WFDC2 and ovarian carcinoma: Interestingly, Dr. Anastasi, E.’s group have found that serum HE4 levels could be used to monitor ovarian cancer patients’ outcome when it was combined together with carbohydrate antigen 72.4 (CA72.4) and CA125 biomarkers, benefiting the detection of ovarian cancer relapse during follow-up [17]; and serum HE4 levels, when combined with Multidetector Computed Tomographic (MDCT) imaging, could be applied to the follow up of the lymph node metastasis status for advanced ovarian cancer patients [18].